表紙
市場調查報告書

多發性骨髓瘤(柯勒病):開發中產品分析

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 229718
出版日期 內容資訊 英文 2289 Pages
訂單完成後即時交付
價格
多發性骨髓瘤(柯勒病):開發中產品分析 Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020
出版日期: 2020年06月30日內容資訊: 英文 2289 Pages
簡介

所謂多發性骨髓瘤是惡性漿細胞在骨髓內部增殖,並產生異常大量特殊蛋白質的癌症。其病因至今不明。高齡者是主要發病者。主要症狀有貧血症及出血、神經損傷、皮膚病變、骨頭壓痛、疼痛、腎功能衰竭等。主要治療方法有化療及放射療法、免疫抑制劑、外科手術等。

本報告提供全球各國治療多發性骨髓瘤(柯勒病)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

多發性骨髓瘤概要

治療藥的開發

  • 多發性骨髓瘤開發中產品:概要
  • 多發性骨髓瘤開發中產品:比較分析

各企業開發中的多發性骨髓瘤治療藥

大學/研究機關研究中的多發性骨髓瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

多發性骨髓瘤治療藥:開發中的產品一覽(各企業)

多發性骨髓瘤治療藥:研究中的產品一覽(各大學/研究機關)

多發性骨髓瘤開發治療藥的企業

多發性骨髓瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

多發性骨髓瘤治療藥:暫停開發的產品

多發性骨髓瘤治療藥:中止開發的產品

多發性骨髓瘤相關產品的開發里程碑

  • 最新消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12325IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides an overview of the Multiple Myeloma (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 10, 105, 118, 4, 10, 165, 29 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 19, 9, 32 and 8 molecules, respectively.

Multiple Myeloma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Myeloma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Myeloma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Multiple Myeloma (Kahler Disease) - Overview
  • Multiple Myeloma (Kahler Disease) - Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
  • Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Drug Profiles
  • Multiple Myeloma (Kahler Disease) - Dormant Projects
  • Multiple Myeloma (Kahler Disease) - Discontinued Products
  • Multiple Myeloma (Kahler Disease) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Agenus Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Antengene Corp, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Multitude therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Starton Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Suzhou Maximum Bio-tech Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by T-CURX GmbH, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Oncology Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Triterpenoid Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Wugen Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by XNK Therapeutics AB, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Zhengda Tianqing Pharmaceutical Group Co Ltd, H1 2020
  • Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H1 2020
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2020
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020